Bio-Techne Corporation has announced an agreement for Mdxhealth SA to acquire its Exosome Diagnostics Inc. business, which includes the ExoDx Prostate $(EPI)$ test, a CLIA-certified clinical laboratory, and related assets. Under the terms of the agreement, Bio-Techne will receive $5 million in MDXH stock, along with future considerations. The transaction is expected to close in the first quarter of Bio-Techne's fiscal 2026. Bio-Techne will maintain access to the proprietary exosome-based technology for ongoing kit development. Mdxhealth views the acquisition as a strategic fit to bolster its presence in the urology and prostate cancer diagnostics sector.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.